New Jersey has been at the center of medical innovation for well over a century – and remains so. We are fortunate to be represented by 14 federal legislators who recognize this and also are all strongly committed – as is our biopharmaceutical sector – to patients and the advancement of the human condition. With H.R. 3’s future in the United States Senate uncertain, we look forward to renewing our efforts with our congressional delegation to find a balanced way to lower health care costs while also encouraging medical innovation that reflects their thoughtful approach, learned insights, policy acumen and responsible governance. Please read more here.